Background
Methods
Model overview
Strategies
Annual screening – TST or QFT
Targeted screening – TST or QFT
Post-exposure screening only – TST or QFT
Key variables and model assumptions
Parameter | Base-case value | Range | References |
---|---|---|---|
Prevalence of latent tuberculosis infection (LTBI) at the time of hire (before baseline testing) | 10.0% | (10–30%) | [6] |
Probability of being recently infected among those with LTBI at baseline | 16.7% | (10–30%) | Model assumption |
Proportion of healthcare workers (HCWs) performing high-risk activities | 27.0% | (10–30%) | [16] |
Annual risk of TB exposure in HCWs performing high-risk activities: | |||
Base-case scenario | 4.4% | (0–40%) | |
Alternate scenario assuming higher risks | 13.1% | (0–40%) | |
Annual risk of TB exposure in HCWs performing intermediate-risk activities: | |||
Base-case scenario | 1.3% | (0–15%) | |
Alternate scenario assuming higher risks | 4.4% | (0–15%) | |
Probability of acquiring new TB infection given exposure | 22.9% | (0–30%) | [18] |
Adherence of HCWs to annual screening (mandatory for continued employment) | 100% | (50–100%) | Model assumption |
Probability that TB exposure is recognised | 75.0% | (50–100%) | Model assumption |
Probability of being screened after TB exposure is recognised (tuberculin skin test) | 88.8% | (50–100%) | [19] |
Probability of being screened after TB exposure is recognised (QuantiFERON®-TB-Gold) | 95.0% | (50–100%) | [20] |
Sensitivity of tuberculin skin test in serial testing | 95.0% | (70–100%) | |
Sensitivity of QuantiFERON®-TB-Gold in serial testing | 95.0% | (70–100%) | |
Specificity of tuberculin skin test for serial testing, after baseline negative test | 97.0% | (70–100%) | [23] |
Specificity of QuantiFERON®-TB-Gold for serial testing after baseline negative test | 95.0% | (70–100%) | |
Efficacy of isoniazid preventive treatment | 90.0% | (80–100%) | [42] |
Probability that isoniazid is recommended to worker after conversion on repeat testing | 100% | (50–100%) | Model assumption |
Probability that worker with conversion starts isoniazid treatment, after recommendation to take it | 82.9% | (50–100%) | [43] |
Probability that isoniazid treatment is completed, once started | 47.3% | (40–100%) | [43] |
Risk of mild isoniazid-induced hepatitis | 0.1% | [44] | |
Risk of fatal isoniazid-induced hepatitis | 0.002% | [44] | |
Annual risk of progression from LTBI to active TB for recently infected (≤2 years since onset of infection) | 2.5% | (0–2.5%) | [21] |
Annual risk of progression from LTBI to active TB for remotely infected (>2 years since onset of infection) | 0.1% | [22] | |
Risk of death from active TB | 4.6% | (0–10%) | [45] |
Risk of major adverse event with treatment for active TB | 5.1% | [44] | |
Risk of death, given major adverse event with treatment for active TB | 1.5% | [44] | |
Costs (in 2015 CAN dollars; $1 CAN = $0.77 US) | |||
Diagnosis for active TB disease | $354 | ||
Inpatient treatment of active TB disease | $13,063 | [49] | |
Outpatient treatment of active TB disease | $3,748 | [50] | |
Tuberculin skin test | $15 | ($10–30) | [51] |
QuantiFERON®-TB-Gold | $50 | ($10–50) | [51] |
Complete treatment for LTBI | $591 | [52] | |
Incomplete treatment for LTBI | $272 | [52] | |
Isoniazid-induced hepatitis (mild) | $400 | [53] | |
Isoniazid-induced hepatitis (fatal) | $13,078 | [53] | |
Quality of life adjustments: QALYs lost per year | |||
Active TB disease treatment | 0.15 | (0.10–0.30) | |
Latent TB treatment | 0.03 | (0–0.05) |
Outcomes and sensitivity analyses
Results
Base-case analysis
Strategy | Cost in 2015 $CAN | QALYs | New active TB cases | Deaths due to active TB | Deaths due to adverse event to treatment of active TB | Deaths due to adverse event to treatment of LTBI | True positive results | False positive results |
---|---|---|---|---|---|---|---|---|
Post-exposure screening only | ||||||||
Tuberculin Skin Test | $66,387 | 15,239.98 | 3.03 | 0.13 | 0.0023 | 0.00036 | 63 | 6 |
QuantiFERON®-TB-Gold | $77,521 | 15,239.85 | 2.97 | 0.13 | 0.0023 | 0.00040 | 67 | 11 |
Targeted screening | ||||||||
Tuberculin Skin Test | $151,517 | 15,237.96 | 2.83 | 0.12 | 0.0022 | 0.00093 | 67 | 109 |
QuantiFERON®-TB-Gold | $263,660 | 15,236.90 | 2.86 | 0.13 | 0.0022 | 0.00120 | 63 | 161 |
Annual screening | ||||||||
Tuberculin Skin Test | $404,956 | 15,231.85 | 2.68 | 0.12 | 0.0020 | 0.00258 | 75 | 413 |
QuantiFERON®-TB-Gold | $817,695 | 15,227.92 | 2.80 | 0.12 | 0.0021 | 0.00362 | 64 | 607 |
Strategy | Cost in 2015 $CAN | QALYs | New active TB cases | Deaths due to active TB | Deaths due to adverse event to treatment of active TB | Deaths due to adverse event to treatment of LTBI | True positive results | False positive results |
---|---|---|---|---|---|---|---|---|
Post-exposure screening only | ||||||||
Tuberculin Skin Test | $198,480 | 15,234.05 | 8.90 | 0.39 | 0.0068 | 0.00109 | 195 | 17 |
QuantiFERON®-TB-Gold | $228,809 | 15,233.75 | 8.73 | 0.38 | 0.0067 | 0.00119 | 201 | 30 |
Targeted screening | ||||||||
Tuberculin Skin Test | $257,670 | 15,232.84 | 8.18 | 0.36 | 0.0063 | 0.00152 | 193 | 96 |
QuantiFERON®-TB-Gold | $365,397 | 15,231.90 | 8.23 | 0.36 | 0.0063 | 0.00177 | 184 | 146 |
Annual screening | ||||||||
Tuberculin Skin Test | $487,837 | 15,227.38 | 7.64 | 0.33 | 0.0058 | 0.00307 | 203 | 373 |
QuantiFERON®-TB-Gold | $868,662 | 15,223.94 | 7.95 | 0.35 | 0.0061 | 0.00395 | 174 | 553 |
Strategy | Cost in 2015 $Can | Incremental cost | QALYs | Increment in QALYs | Incremental cost per QALY gaineda
| New active TB cases | Increment in active TB cases prevented | Incremental cost per additional TB case preventeda
|
---|---|---|---|---|---|---|---|---|
Post-exposure screening only | ||||||||
Tuberculin Skin Test | $66,387 | — | 15,239.98 | –– | –– | 3.03 | — | — |
QuantiFERON®-TB-Gold | $77,521 | $11,134 | 15,239.85 | –0.13 | –– (Dominatedb) | 2.97 | 0.06 | $197,017 |
Targeted screening | ||||||||
Tuberculin Skin Test | $151,517 | $85,130 | 15,237.96 | –2.02 | –– (Dominatedb) | 2.83 | 0.14 | $517,437c
|
QuantiFERON®-TB-Gold | $263,660 | $197,273 | 15,236.90 | –3.07 | –– (Dominatedb) | 2.86 | –0.04 | — (Dominatedb) |
Annual screening | ||||||||
Tuberculin Skin Test | $404,956 | $338,569 | 15,231.85 | –8.12 | –– (Dominatedb) | 2.68 | 0.15 | $1,717,539 |
QuantiFERON®-TB-Gold | $817,695 | $751,308 | 15,227.92 | –12.06 | –– (Dominatedb) | 2.80 | –0.12 | — (Dominatedb) |
Alternate scenario with higher worker risks
Strategy | Cost in 2015 $Can | Incremental cost | QALYs | Increment in QALYs | Incremental cost per QALY gaineda
| New active TB cases | Increment in active TB cases prevented | Incremental cost per additional TB case preventeda
|
---|---|---|---|---|---|---|---|---|
Post-exposure screening only | ||||||||
Tuberculin Skin Test | $198,480 | — | 15,234.05 | — | — | 8.90 | — | — |
QuantiFERON®-TB-Gold | $228,809 | $30,329 | 15,233.75 | –0.30 | — (Dominatedb) | 8.73 | 0.17 | — (Extended dominancec) |
Targeted screening | ||||||||
Tuberculin Skin Test | $257,670 | $59,190 | 15,232.84 | –1.22 | — (Dominatedb) | 8.18 | 0.55 | $52,552 |
QuantiFERON®-TB-Gold | $365,397 | $166,917 | 15 231.90 | –2.15 | — (Dominatedb) | 8.23 | –0.05 | — (Dominatedb) |
Annual screening | ||||||||
Tuberculin Skin Test | $487,837 | $289,357 | 15,227.38 | –6.68 | — (Dominatedb) | 7.64 | 0.54 | $426,678 |
QuantiFERON®-TB-Gold | $868,662 | $670,182 | 15,223.94 | –10.11 | — (Dominatedb) | 7.95 | –0.31 | — (Dominatedb) |
Sensitivity analyses
Strategy | Cost in 2015 $CAN | QALYs | New active TB cases | Deaths due to active TB | Deaths due to adverse event to treatment of active TB | Deaths due to adverse event to treatment of LTBI | True positive results | False positive results |
---|---|---|---|---|---|---|---|---|
Post-exposure screening only | ||||||||
Tuberculin SKIN Test | $66,387 | 15,239.98 | 3.03 | 0.13 | 0.0023 | 0.00036 | 63 | 6 |
QuantiFERON®-TB-Gold | $77,521 | 15,239.85 | 2.97 | 0.13 | 0.0023 | 0.00040 | 67 | 11 |
Targeted screening | ||||||||
Tuberculin Skin Test | $151,517 | 15,237.96 | 2.83 | 0.12 | 0.0022 | 0.00093 | 67 | 109 |
QuantiFERON®-TB-Gold | $260,558 | 15,239.67 | 2.67 | 0.12 | 0.0020 | 0.00049 | 78 | 17 |
Annual screening | ||||||||
Tuberculin Skin Test | $404,956 | 15,231.85 | 2.68 | 0.12 | 0.0020 | 0.00258 | 75 | 413 |
QuantiFERON®-TB-Gold | $801,059 | 15,238.94 | 2.44 | 0.11 | 0.0019 | 0.00072 | 93 | 46 |